Evidence map›Paper›PMID 25277410›Full record

ArticleGastroenterology2015

MicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.

QiQi Zhou, Stefan Costinean, Carlo M Croce, Alan R Brasier, Shehzad Merwat, Scott A Larson, Sarpreet Basra, G Nicholas Verne

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 1 synthesis or guideline pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

QiQi ZhouDepartment of Medicine, University of Texas Medical Branch, Galveston, Texas; Department of Veteran Affairs, Cincinnati VA Medical Center, Cincinnati, Ohio.
Stefan CostineanComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Carlo M CroceComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Alan R BrasierDepartment of Medicine, University of Texas Medical Branch, Galveston, Texas.
Shehzad MerwatDepartment of Medicine, University of Texas Medical Branch, Galveston, Texas.
Scott A LarsonDepartment of Medicine, University of Texas Medical Branch, Galveston, Texas.
Sarpreet BasraDepartment of Medicine, University of Texas Medical Branch, Galveston, Texas.
G Nicholas VerneDepartment of Medicine, Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: gverne@tulane.edu.
The University of Texas Medical Branch at Galveston · USThe Ohio State University · USTulane University · US

Funding

Mechanisms of Altered Gastrointestinal DysfunctionR01DK099052 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI VERNE, GEORGE NICHOLAS, ZHOU, QIQI · 2013 to 2023
$3.0M
Randomized Placebo-Controlled Trial of Glutamine for Patients with IBSR21AT005291 · NCCIH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI VERNE, GEORGE NICHOLAS · 2010 to 2012
$566k
NCCIH NIH HHS AT005291NCCIH NIH HHS R21 AT005291NIDDK NIH HHS DK099052NIDDK NIH HHS R01 DK099052
6 · The paper itself

Abstract

BACKGROUND &

aimsSome patients with irritable bowel syndrome with diarrhea (IBS-D) have intestinal hyperpermeability, which contributes to their diarrhea and abdominal pain. MicroRNA 29 (MIR29) regulates intestinal permeability in patients with IBS-D. We investigated and searched for targets of MIR29 and investigated the effects of disrupting Mir29 in mice.

methodsWe investigated expression MIR29A and B in intestinal biopsies collected during endoscopy from patients with IBS (n = 183) and without IBS (controls) (n = 36). Levels were correlated with disease phenotype. We also generated and studied Mir29(-/-) mice, in which expression of Mir29a and b, but not c, is lost. Colitis was induced by administration of 2,4,6-trinitrobenzenesulfonic acid; intestinal tissues were collected and permeability was assessed. Microarray analysis was performed using tissues from Mir29(-/-) mice. Changes in levels of target genes were measured in human colonic epithelial cells and small intestinal epithelial cells after knockdown of MIR29 with anti-MIRs.

resultsIntestinal tissues from patients with IBS-D (but not IBS with constipation or controls) had increased levels of MIR29A and B, but reduced levels of Claudin-1 (CLDN1) and nuclear factor-κB-repressing factor (NKRF). Induction of colitis and water avoidance stress increased levels of Mir29a and Mir29b and intestinal permeability in wild-type mice; these increased intestinal permeability in colons of far fewer Mir29(-/-) mice. In microarray and knockdown experiments, MIR29A and B were found to reduce levels of NKRF and CLDN1 messenger RNA, and alter levels of other messenger RNAs that regulate intestinal permeability.

conclusionsBased on experiments in knockout mice and analyses of intestinal tissue samples from patients with IBS-D, MIR29 targets and reduces expression of CLDN1 and NKRF to increase intestinal permeability. Strategies to block MIR29 might be developed to restore intestinal permeability in patients with IBS-D.

Indexed as

AnimalsCase-Control StudiesCell LineClaudin-1ColitisColonDisease Models, AnimalDown-RegulationGene Knockdown TechniquesGenetic Predisposition to DiseaseHumansInflammatory Bowel DiseasesMaleMice, Inbred C57BLMice, KnockoutMicroRNAsClaudin-1CLDN1 protein, humanCldn1 protein, mouseMicroRNAsMIRN29a microRNA, humanMIRN29 microRNA, mouseNKRF protein, humanNKRF protein, mouseRepressor ProteinsRNA, MessengerTrinitrobenzenesulfonic AcidGene RegulationIntestinal Barrier FunctionMouse ModelmRNA Processing

Identifiers

PMID25277410
PMCPMC4303568
OpenAlexW2122935354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.